Heart Failure, Congestive Clinical Trial
Official title:
ENABLE: CHF-PC (Educate, Nurture, Advise, Before Life Ends: Comprehensive Heartcare for Patients and Caregivers)
Verified date | May 2020 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Early palliative care (EPC) is recommended but rarely integrated with advanced
heart failure (HF) care. This pilot study engaged patients and family caregivers to study the
feasibility and site differences in a two-site EPC trial, ENABLE CHF-PC (Educate, Nurture,
Advise, Before Life Ends Comprehensive Heartcare for Patients and Caregivers).
An EPC feasibility study (4/1/14-8/31/15) was conducted for patients with New York Heart
Association (NYHA) Functional Class III/IV HF and their caregivers in academic medical
centers in the northeast and southeast U.S. The EPC intervention comprised: 1) an in-person
palliative care consultation; and 2) telephonic nurse coach sessions and monthly calls.
Patient- and caregiver-reported outcomes were collected for quality of life (QOL), symptom,
health, anxiety, and depression outcomes at baseline, 12- and 24-weeks. Linear mixed-models
were used to assess baseline to week 24 longitudinal changes. The intervention was tailored
to rural, older adults (ageā„65) with advanced HF in reducing HF morbidity and improving
patient and caregiver QOL and quality of care.
Status | Completed |
Enrollment | 62 |
Est. completion date | December 31, 2015 |
Est. primary completion date | December 31, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Patient Inclusion Criteria: 1. English-speaking and able to complete baseline interview 2. Age =65 (Age criteria was reduced to =50 y/o given regional experience with HF population) 3. NYHA Stage III/IV heart failure; American College of Cardiology (ACC) Class C/D 4. Have a land-based phone or reliable cellular phone service 5. Have an agreeable partner willing to participate in the study* (recommended) *In our previous studies we have not required patients to have a care partner for eligibility. In this study it is essential that we have an adequate number of caregivers to test the caregiver intervention. Therefore patients without a care partner will still be considered but the final study sample size may need to be adjusted to ensure an adequate caregiver sample. Patient Exclusion Criteria: 1. Non-correctable hearing loss 2. Dementia or significant confusion (as measured by a Callahan score of =3 3. Diagnostic and Statistical Manual (DSM) -IV Axis I diagnosis (e.g. schizophrenia, bipolar disorder) or active substance use disorder Caregiver Inclusion Criteria: 1. "Caregiver" is identified by the patient as "a person who knows you well and is involved in your medical care". May be a spouse or adult family member or friend living in the same household or considered by the patient to be the primary caregiver and be willing to participate." 2. English-speaking and able to complete baseline interview 3. Have a land-based phone or reliable cellular phone service. Caregiver Exclusion Criteria: 1. Non-correctable hearing loss. |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Dartmouth-Hitchcock Medical Center, Dartmouth College, Dartmouth-Hitchcock Heart & Vascular Center | Lebanon | New Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | National Palliative Care Research Center (NPCRC) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of recruitment for a large-scale RCT. | Number (#) of participants enrolled within 2 years compared to study's target goal. | From Date of Enrollment to 24 Weeks | |
Primary | Feasibility of retention for a large-scale RCT. | Number (#) of participants completing study activities by 24 weeks. | From Date of Enrollment to 24 Weeks | |
Primary | Feasibility of intervention completion for a large-scale RCT. | Number (#) of participants completing all intervention sessions by 24 weeks. | From Date of Enrollment to 24 Weeks | |
Primary | Feasibility of measurement completion for a large-scale RCT. | Number (#) of participants completing outcomes measures by 24 weeks. | From Date of Enrollment to 24 Weeks | |
Secondary | Patient Quality of Life | Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered HF-specific questionnaire that describes physical limitations (1 item), symptoms (frequency-4 items,severity-3 items, change over time-1 item) self-efficacy/ knowledge (2 items), social interference (1 item) and QOL (3 items). Individual domains show high internal consistency reliability (Cronbach's alpha's .62-.90). It is reported to take 6 minutes to complete. Two summary scores (functional and clinical) can be calculated. It is reported to be more sensitive to clinical change than other HF-specific measures. Scores range from 0-100 wherein higher scores indicate better health status. | Baseline, week 12, and week 24. | |
Secondary | Patient Quality of Care | Patient Assessment of Chronic Illness Care (PACIC) is a 20-item patient reported measure of chronic illness care (CIC) health counseling behaviors. It consists of the five CIC constructs: patient activation, delivery system/ decision support, goal setting, problem-solving, and follow-up/ coordination. It has good internal consistency with Cronbach alphas ranging from .78 to .90, and test-retest reliability, estimated by intracluster correlation coefficient (ICC), was at least 0.77. | Baseline, week 12, and week 24. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |